Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide

CONCLUSIONS: The requirement for calibration to replicate the outcomes observed in SUSTAIN 6 suggests that the reductions in risk of cardiovascular complications observed with once-weekly semaglutide cannot be solely explained by differences in conventional risk factors. Accurate estimation of the risk of diabetes-related complications using methods such as calibration is important to ensure accurate cost-effectiveness analyses are conducted.PMID:37525970 | DOI:10.1080/13696998.2023.2240957

Source: Journal of Medical Economics - August 1, 2023 Category: Health Management Authors: Sasha Berry Barrie Chubb Annabel Acs Edel Falla Akanksha Verma Samuel Jp Malkin Barnaby Hunt Andrew J Palmer Source Type: research